Results 151 to 160 of about 26,835 (181)
Single-cell-based identification of drug synergy with immunotherapy via tumor microenvironment remodeling. [PDF]
J Immunother CancerWang Z +18 more
europepmc +1 more source
Exploiting mitochondrial dysfunction to overcome BRAF inhibitor resistance in advanced melanoma: the role of disulfiram as a copper ionophore. [PDF]
Cell Death DisZhao B +9 more
europepmc +1 more source
Combined BRAF/MEK inhibition for BRAF-mutant melanoma brain metastases in pregnancy: A case report. [PDF]
Oncol LettMelus J +8 more
europepmc +1 more source
Some of the next articles are maybe not open access.
Related searches:
Related searches:
Reactions Weekly, 2018
The activating BRAF mutation V600E and related mutations in this codon are most important for the activation of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signalling pathway in melanoma. BRAF V600E mutations have been detected in ~40% of melanoma patients and BRAF V600K mutations in ~5% of melanoma patients.
Claus, Garbe, Thomas K, Eigentler
+7 more sources
The activating BRAF mutation V600E and related mutations in this codon are most important for the activation of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signalling pathway in melanoma. BRAF V600E mutations have been detected in ~40% of melanoma patients and BRAF V600K mutations in ~5% of melanoma patients.
Claus, Garbe, Thomas K, Eigentler
+7 more sources
Reactions Weekly, 2014
The activating BRAF mutation V600E and related mutations in this codon are most important for the activation of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signalling pathway in melanoma. BRAF V600E mutations have been detected in ~40% of melanoma patients and BRAF V600K mutations in ~5% of melanoma patients.
Claus, Garbe +2 more
+5 more sources
The activating BRAF mutation V600E and related mutations in this codon are most important for the activation of the RAS/RAF/MEK/ERK mitogen-activated protein kinase (MAPK) signalling pathway in melanoma. BRAF V600E mutations have been detected in ~40% of melanoma patients and BRAF V600K mutations in ~5% of melanoma patients.
Claus, Garbe +2 more
+5 more sources